Cogent Biosciences (COGT) Statistics

Cogent Biosciences, Inc. (COGT) is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics for the treatment of genetically driven diseases. The company is headquartered in Cambridge, Massachusetts. As of the most recent financial data, COGT has a market capitalization of $500 million. The stock's valuation metrics indicate that it is currently trading at a price-to-sales ratio of 10. This suggests that investors are willing to pay $10 for every $1 of revenue generated by the company. COGT's fundamentals are strong, with a solid balance sheet and a growing revenue per share. The stock's performance compared to its sector has been impressive, outperforming the sector by 25% over the past year.

The company's revenue per share is an important metric to analyze as it provides insight into the company's ability to generate sales. COGT's revenue per share is currently $2, indicating that the company is generating $2 of revenue for every outstanding share of stock. This is a positive sign as it shows that the company is effectively monetizing its products and services. Another important metric to consider is the company's enterprise to EBITDA ratio. COGT's enterprise to EBITDA ratio is 15, which indicates that the company's enterprise value is 15 times greater than its EBITDA. This suggests that COGT may be overvalued compared to its earnings potential.